Scarica l'app Stockscreener
2.83
1.43%
0.04
Dopo l'orario di chiusura:
2.93
0.10
+3.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTXR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.79
Aprire:
$2.83
Volume 24 ore:
101.03K
Relative Volume:
0.38
Capitalizzazione di mercato:
$24.32M
Reddito:
-
Utile/perdita netta:
$-32.54M
Rapporto P/E:
-12.86
EPS:
-0.22
Flusso di cassa netto:
$-29.06M
1 W Prestazione:
-10.16%
1M Prestazione:
-27.62%
6M Prestazione:
-87.84%
1 anno Prestazione:
-81.89%
Intervallo 1D:
$2.60
$2.90
Intervallo di 1 settimana:
$2.60
$3.40
Portata 52W:
$2.44
$26.75
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Nome
Citius Pharmaceuticals Inc
Settore
Industria
Telefono
(908) 967-6676
Indirizzo
11 COMMERCE DRIVE, CRANFORD, NJ
Confronta CTXR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
2.83 | 24.32M | 0 | -32.54M | -29.06M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
Citius Pharmaceuticals Inc Borsa (CTXR) Ultime notizie
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital - Defense World
Citius Pharma secures $3 million in direct offering By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15% - Benzinga
Citius Pharma secures $3 million in direct offering - Investing.com
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - PR Newswire
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharma gears up for LYMPHIR immunotherapy launch By Investing.com - Investing.com Australia
Citius Pharma gears up for LYMPHIR immunotherapy launch - Investing.com
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to “Buy” at D. Boral Capital - Defense World
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR) - MSN
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Yahoo Finance
Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target - Quantisnow
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Re - GuruFocus.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Yahoo Finance
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World
Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com
Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals Inc Azioni (CTXR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):